文献速递乳腺技术与安全PET

18F-氟雌二醇:当前应用与未来方向

18F-Fluoroestradiol: Current Applications and Future Directions.
PubMed 文献 · Radiographics · 2023-01-01

本文综述了18F-氟雌二醇(FES)PET在雌激素受体(ER)阳性复发或转移性乳腺癌中的获批临床应用,包括确定活检靶病灶、体内评估活检证实的ER阳性病灶以及评估ER的空间和时间异质性;FES于2020年5月获美国FDA批准作为活检的辅助手段用于ER阳性复发或转移性乳腺癌患者。

要点

  • FES与表达ER细胞核内的ER结合,可全身在体评估ER表达。
  • FES获批用于ER阳性复发或转移性乳腺癌,作为活检的辅助手段。
  • FES可用于确定活检靶病灶、评估活检证实的ER阳性病灶及ER异质性。

核心结论

  • FES是精准医学的一个例子,已被用于优化乳腺癌患者的诊疗。

研究设计与样本

  • 本文为综述,聚焦FES在美国获批的用途。
  • 美国FDA于2020年5月批准18F-FES PET放射性示踪剂用于ER阳性复发或转移性乳腺癌患者的临床使用,作为活检的辅助手段。

诊断标准与关键数值

  • 约80%的新诊断乳腺癌为激素受体(HR)阳性,定义为雌激素受体(ER)和/或孕激素受体(PR)阳性。

临床应用与阅片要点

  • FES获批用途包括确定用于确认性活检的靶病灶。
  • FES可用于在体内评估活检证实的ER阳性病灶。
  • FES可用于评估ER的空间和时间异质性。

局限性

  • 活检标本免疫组化评估ER表达存在采样误差、假阴性结果、活检部位困难或不可及以及无法同步和连续评估所有转移部位以识别空间和/或时间ER异质性等局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

In the United States, breast cancer is the second leading cause of cancer death in all women and the leading cause of cancer death in Black women. The breast cancer receptor profile, assessed with immunohistochemical staining of tissue samples, allows prediction of outcomes and direction of patient treatment. Approximately 80% of newly diagnosed breast cancers are hormone receptor (HR) positive, which is defined as estrogen receptor (ER) and/or progesterone receptor (PR) positive. Patients with ER-positive disease can be treated with therapies targeting the ER; however, the assessment of ER expression with immunohistochemical staining of biopsy specimens has several limitations including sampling error, false-negative results, challenging or inaccessible biopsy sites, and the inability to synchronously and serially assess all metastatic sites to identify spatial and/or temporal ER heterogeneity. In May 2020, after decades of research, the U.S. Food and Drug Administration approved the PET radiotracer fluorine 18 (18F) fluoroestradiol (FES) for clinical use in patients with ER-positive recurrent or metastatic breast cancer as an adjunct to biopsy. FES binds to the ER in the nucleus of ER-expressing cells, enabling whole-body in vivo assessment of ER expression. This article is focused on the approved uses of FES in the United States, including identification of a target lesion for confirmatory biopsy, in vivo assessment of biopsy-proven ER-positive disease, and evaluation of spatial and temporal ER heterogeneity. FES is an example of precision medicine that has been leveraged to optimize the care of patients with breast cancer. © RSNA, 2023 See the invited commentary by Fowler in this issue. Quiz questions for this article are available through the Online Learning Center.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. O'Brien SR, Edmonds CE, Lanzo SM, et al. 18F-Fluoroestradiol: Current Applications and Future Directions. Radiographics. 2023. PMID: 36821506. doi:10.1148/rg.220143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。